Poxel Enters Reorganization Proceedings as Clinical-Stage Biotech Faces Financial Restructuring
核心洞察
Poxel SA, a clinical-stage biopharmaceutical company developing treatments for metabolic diseases, has entered judicial reorganization proceedings following a court hearing on August 5, 2025.
The company will continue operations during a six-month observation period while exploring options including a continuation plan to maintain its drug development activities.
Poxel's pipeline includes PXL065 for MASH (搜索) treatment, which met its primary endpoint in the Phase 2 DESTINY-1 trial, and PXL770 for rare metabolic disorders.
Poxel SA, a clinical-stage biopharmaceutical company focused on metabolic diseases, has entered judicial reorganization proceedings after filing for insolvency with the Lyon Court of Economic Activities. The French biotech company announced on August 8, 2025, that the court decided to initiate reorganization proceedings following a hearing held on August 5, 2025.
The company had initially filed for insolvency on July 29, 2025, requesting the opening of reorganization proceedings. Under the court's decision, Poxel will continue to operate during a six-month observation period in accordance with legal provisions, during which the company will examine all available options to continue its activities, including developing a continuation plan.
Clinical Pipeline Remains Active
Despite the financial restructuring, Poxel maintains an active clinical pipeline targeting chronic serious diseases with metabolic pathophysiology. The company's lead program, PXL065, a deuterium-stabilized R-pioglitazone for the treatment of metabolic dysfunction-associated steatohepatitis (搜索) (MASH (搜索)), successfully met its primary endpoint in the streamlined Phase 2 DESTINY-1 trial.
In rare diseases, Poxel is developing PXL770, described as a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK (搜索)) activator. This compound is being investigated for the treatment of adrenoleukodystrophy (搜索) (ALD (搜索)) and autosomal dominant polycystic kidney disease (搜索) (ADPKD (搜索)).
Commercial Partnership Provides Revenue Stream
The company has an established revenue stream through its partnership with Sumitomo Pharma for TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction. The drug is currently marketed for the treatment of type 2 diabetes (搜索) in Japan, with Poxel expecting to receive royalties and sales-based payments from this strategic partnership.
Trading Resumption and Stakeholder Communication
Poxel requested Euronext to resume trading of its shares (Euronext: POXEL - FR0012432516) as of August 11, 2025, at market opening. The company has committed to keeping all stakeholders informed of developments in its situation and the progress of the reorganization proceedings.
Headquartered in Lyon, France, with subsidiaries in Boston, Massachusetts, and Tokyo, Japan, Poxel is listed on Euronext Paris. The company stated it will continue to examine all available options during the observation period to maintain its drug development activities and operations.